Cargando…

Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides

OBJECTIVE: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). METHODS: Retrospective analysis of Ig concentrations and peripheral B...

Descripción completa

Detalles Bibliográficos
Autores principales: Venhoff, Nils, Effelsberg, Nora M., Salzer, Ulrich, Warnatz, Klaus, Peter, Hans Hartmut, Lebrecht, Dirk, Schlesier, Michael, Voll, Reinhard E., Thiel, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357389/
https://www.ncbi.nlm.nih.gov/pubmed/22629432
http://dx.doi.org/10.1371/journal.pone.0037626
_version_ 1782233665501134848
author Venhoff, Nils
Effelsberg, Nora M.
Salzer, Ulrich
Warnatz, Klaus
Peter, Hans Hartmut
Lebrecht, Dirk
Schlesier, Michael
Voll, Reinhard E.
Thiel, Jens
author_facet Venhoff, Nils
Effelsberg, Nora M.
Salzer, Ulrich
Warnatz, Klaus
Peter, Hans Hartmut
Lebrecht, Dirk
Schlesier, Michael
Voll, Reinhard E.
Thiel, Jens
author_sort Venhoff, Nils
collection PubMed
description OBJECTIVE: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). METHODS: Retrospective analysis of Ig concentrations and peripheral B cell counts in 55 AAV patients. RESULTS: CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to 9.17 g/L (8.04-9.90) (p = 0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p = 0.046) and IgA 2.58 g/L (1.71-3.48) to 1.58 g/L (1-31-2.39) (p = 0.056) at a median follow-up time of 4 months. IgG remained significantly below the initial value at 14.5 months and 30 months analyses. Subsequent RTX treatment in patients that had previously received CYC resulted in a further decline in Ig levels from pre RTX IgG 9.84 g/L (8.71-11.60) to 7.11 g/L (5.75-8.77; p = 0.007), from pre RTX IgM 0.84 g/L (0.63-1.18) to 0.35 g/L (0.23-0.48; p<0.001) and from pre RTX IgA 2.03 g/L (1.37-2.50) to IgA 1.62 g/L (IQR 0.84-2.43; p = 0.365) 14 months after RTX. Treatment with RTX induced a complete depletion of B cells in all patients. After a median observation time of 20 months median B lymphocyte counts remained severely suppressed (4 B-cells/µl, 1.25-9.5, p<0.001). Seven patients (21%) that had been treated with CYC followed by RTX were started on Ig replacement because of severe bronchopulmonary infections and serum IgG concentrations below 5 g/L. CONCLUSIONS: In patients with AAVs, treatment with CYC leads to a decline in immunoglobulin concentrations. A subsequent RTX therapy aggravates the decline in serum immunoglobulin concentrations and results in a profoundly delayed B cell repopulation. Surveying patients with AAVs post CYC and RTX treatment for serum immunoglobulin concentrations and persisting hypogammaglobulinemia is warranted.
format Online
Article
Text
id pubmed-3357389
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-33573892012-05-24 Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides Venhoff, Nils Effelsberg, Nora M. Salzer, Ulrich Warnatz, Klaus Peter, Hans Hartmut Lebrecht, Dirk Schlesier, Michael Voll, Reinhard E. Thiel, Jens PLoS One Research Article OBJECTIVE: To assess the impact of immunosuppressive therapy with cyclophosphamide (CYC) and rituximab (RTX) on serum immunoglobulin (Ig) concentrations and B lymphocyte counts in patients with ANCA-associated vasculitides (AAVs). METHODS: Retrospective analysis of Ig concentrations and peripheral B cell counts in 55 AAV patients. RESULTS: CYC treatment resulted in a decrease in Ig levels (median; interquartile range IQR) from IgG 12.8 g/L (8.15-15.45) to 9.17 g/L (8.04-9.90) (p = 0.002), IgM 1.05 g/L (0.70-1.41) to 0.83 g/L (0.60-1.17) (p = 0.046) and IgA 2.58 g/L (1.71-3.48) to 1.58 g/L (1-31-2.39) (p = 0.056) at a median follow-up time of 4 months. IgG remained significantly below the initial value at 14.5 months and 30 months analyses. Subsequent RTX treatment in patients that had previously received CYC resulted in a further decline in Ig levels from pre RTX IgG 9.84 g/L (8.71-11.60) to 7.11 g/L (5.75-8.77; p = 0.007), from pre RTX IgM 0.84 g/L (0.63-1.18) to 0.35 g/L (0.23-0.48; p<0.001) and from pre RTX IgA 2.03 g/L (1.37-2.50) to IgA 1.62 g/L (IQR 0.84-2.43; p = 0.365) 14 months after RTX. Treatment with RTX induced a complete depletion of B cells in all patients. After a median observation time of 20 months median B lymphocyte counts remained severely suppressed (4 B-cells/µl, 1.25-9.5, p<0.001). Seven patients (21%) that had been treated with CYC followed by RTX were started on Ig replacement because of severe bronchopulmonary infections and serum IgG concentrations below 5 g/L. CONCLUSIONS: In patients with AAVs, treatment with CYC leads to a decline in immunoglobulin concentrations. A subsequent RTX therapy aggravates the decline in serum immunoglobulin concentrations and results in a profoundly delayed B cell repopulation. Surveying patients with AAVs post CYC and RTX treatment for serum immunoglobulin concentrations and persisting hypogammaglobulinemia is warranted. Public Library of Science 2012-05-21 /pmc/articles/PMC3357389/ /pubmed/22629432 http://dx.doi.org/10.1371/journal.pone.0037626 Text en Venhoff et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Venhoff, Nils
Effelsberg, Nora M.
Salzer, Ulrich
Warnatz, Klaus
Peter, Hans Hartmut
Lebrecht, Dirk
Schlesier, Michael
Voll, Reinhard E.
Thiel, Jens
Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
title Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
title_full Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
title_fullStr Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
title_full_unstemmed Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
title_short Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
title_sort impact of rituximab on immunoglobulin concentrations and b cell numbers after cyclophosphamide treatment in patients with anca-associated vasculitides
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3357389/
https://www.ncbi.nlm.nih.gov/pubmed/22629432
http://dx.doi.org/10.1371/journal.pone.0037626
work_keys_str_mv AT venhoffnils impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT effelsbergnoram impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT salzerulrich impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT warnatzklaus impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT peterhanshartmut impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT lebrechtdirk impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT schlesiermichael impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT vollreinharde impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides
AT thieljens impactofrituximabonimmunoglobulinconcentrationsandbcellnumbersaftercyclophosphamidetreatmentinpatientswithancaassociatedvasculitides